| oshpd_id | manufacturer_name | date_reported | ndc_number | drug_product_description | wac_effective_date | wac_increase_amount | wac_after_increase | patent_expiration_date | drug_source_type | unit_sales_volume_in_us | unit_sales_volume_non_public_indicator | gross_sales_us_dollars | gross_sales_us_dollars_non_public_indicator | cost_increase_factors | cost_increase_factors_non_public_indicator | change_improvement_description | change_improvement_non_public_indicator | acquisition_date | company_acquired_from | acquisition_price | acquisition_price_non_public_indicator | acquisition_price_comment | wac_at_acquisition | wac_year_prior_to_acquisition | year_drug_introduced_to_market | wac_at_intro_to_market | supporting_documents | general_comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rx0000315 | Y-mAbs Therapeutics Inc. | 04/10/2025 | 73042020101 | Danyelza 40 mg/10 mL in a single dose vial | 01/01/2025 | 1705.25 | 26065.90 | 02/15/2034 | Single Source Drug | None | None | 65981000 | None | Price is determined after a careful analysis of a number of factors such as: cost of manufacturing, warehousing, storage, distribution, shipping, marketing and regulatory costs. | None | The change in price of the product is not necessarily related to changes in the product but is determined after a careful consideration of how to remain competitive and continue our mission of developing oncology products addressing clear unmet medical needs. | None | None | None | None | None | None | None | None | None | None | None | None |